1. Home
  2. QH vs BOLD Comparison

QH vs BOLD Comparison

Compare QH & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QH

Quhuo Limited American Depository Shares

HOLD

Current Price

$0.10

Market Cap

1.1M

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.43

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
QH
BOLD
Founded
2012
2018
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.1M
36.5M
IPO Year
2019
2024

Fundamental Metrics

Financial Performance
Metric
QH
BOLD
Price
$0.10
$1.43
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
10.6M
138.1K
Earning Date
04-02-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.86
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.96
52 Week High
$10.85
$1.68

Technical Indicators

Market Signals
Indicator
QH
BOLD
Relative Strength Index (RSI) 30.16 49.78
Support Level $0.09 $1.42
Resistance Level $0.11 $1.55
Average True Range (ATR) 0.02 0.09
MACD 0.03 -0.02
Stochastic Oscillator 60.67 24.53

Price Performance

Historical Comparison
QH
BOLD

About QH Quhuo Limited American Depository Shares

Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: